Dermatomyositis Clinical Trials

24 recruiting

Dermatomyositis Trials at a Glance

35 actively recruiting trials for dermatomyositis are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 1 with 9 trials, with the heaviest enrollment activity in Bethesda, Pittsburgh, and Houston. Lead sponsors running dermatomyositis studies include Chongqing Precision Biotech Co., Ltd, National Institute of Environmental Health Sciences (NIEHS), and Peking Union Medical College Hospital.

Browse dermatomyositis trials by phase

Treatments under study

About Dermatomyositis Clinical Trials

Looking for clinical trials for Dermatomyositis? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dermatomyositis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dermatomyositis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 35 trials

Recruiting

Environmental Risk Factors for the Anti-synthetase Syndrome

DermatomyositisPolymyositisMyositis+2 more
National Institute of Environmental Health Sciences (NIEHS)580 enrolled8 locationsNCT01276470
Recruiting
Phase 2

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Dermatomyositis (DM)Juvenile Dermatomyositis (JDM)
National Institute of Environmental Health Sciences (NIEHS)300 enrolled1 locationNCT07111065
Recruiting

Adult and Juvenile Myositis

DermatomyositisInclusion Body MyositisPolymyositis
National Institute of Environmental Health Sciences (NIEHS)1,200 enrolled4 locationsNCT00017914
Recruiting

Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis

Autoinflammatory DiseaseJuvenile Dermatomyositis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)5,000 enrolled1 locationNCT00059748
Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory Myopathy
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting
Phase 2Phase 3

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Idiopathic Inflammatory Myositis (IIM)DERMATOMYOSITIS OR POLYMYOSITIS
Restem, LLC.40 enrolled2 locationsNCT07160205
Recruiting
Not Applicable

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusDermatomyositis+1 more
The First Affiliated Hospital with Nanjing Medical University72 enrolled1 locationNCT07558850
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Polymyositis, Dermatomyositis
AstraZeneca240 enrolled234 locationsNCT06455449
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 3

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

DermatomyositisPolymyositis
Pfizer211 enrolled24 locationsNCT06698796
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting

Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)

Dermatomyositis
University of Pennsylvania300 enrolled1 locationNCT02945345
Recruiting

Rheumatology Patient Registry and Biorepository

Rheumatoid ArthritisLyme DiseaseSarcoidosis+17 more
Yale University5,000 enrolled1 locationNCT04402086
Recruiting
Not Applicable

RCT of Tocilizumab for Anti-MDA5+DM

Dermatomyositis
Peking Union Medical College Hospital110 enrolled1 locationNCT07377058
Recruiting

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

DermatomyositisInflammatory MyopathyInclusion Body Myositis+9 more
Myositis International Health & Research Collaborative Alliance Foundation700 enrolled1 locationNCT07374107
Recruiting

Panniculitis in Dermatomyositis

PanniculitisDermatomyositis
University Hospital, Strasbourg, France20 enrolled1 locationNCT07345949
Recruiting

Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLES

Dermatomyositis
Centre Hospitalier Universitaire de la Guadeloupe10 enrolled1 locationNCT07265999
Recruiting
Phase 2

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

Dermatomyositis
The Cleveland Clinic15 enrolled1 locationNCT06857240
Recruiting
Phase 1Phase 2

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease

Systemic Lupus ErythematosusDermatomyositisPolymyositis+1 more
Miltenyi Biomedicine GmbH24 enrolled1 locationNCT06347718
Recruiting
Phase 1

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

Systemic Sclerosis (SSc)Polyarticular Juvenile Idiopathic ArthritisPrimary Sjogren's Syndrome+1 more
Chongqing Precision Biotech Co., Ltd11 enrolled1 locationNCT07184450